JPMorgan Puts $135 Target on Dianthus After Starting Coverage
Lead drug claseprubart (also known as DNTH103) plus $1.2B cash into 2030.
/ 5 items
#DNTH↓
Raymond James Bullish on Dianthus as Claseprubart Outperforms Expectations in Early CAPTIVATE Results
Raymond James reiterated its Strong Buy rating and $125 price target on Dianthus after the company reported strong early data from the Phase 3 CAPTIVATE study of claseprubart in CIDP.
Sanofi’s Phase 3 CIDP Failure Hits Riliprubart and Raises Doubts for Dianthus’ Claseprubart
Sanofi discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for Dianthus’ claseprubart (C1s inhibitor).
Dianthus Therapeutics Scores Early Phase 3 Win in CIDP: Claseprubart Hits GO Decision Ahead of Schedule
Dianthus shares surged after an early “GO” decision in Phase 3 CAPTIVATE trial of claseprubart for CIDP. Strong 50%+ response rate and clean safety profile reported. Top-line data expected by end of 2026.
Dianthus Therapeutics: Myasthenia Gravis Drug Shows Promise
Dianthus's Claseprubart shows promising Phase 2 results for gMG, significantly improving daily activities & muscle strength with good safety. Plans for a convenient self-administered dose and a Phase 3 trial in 2026.